NANOFILAMENT
IMMUNOTHERAPY
TATUM is a therapeutic company advancing next generation immunotherapies. Using a modular synthetic biology platform, we develop multimodal nanofilaments igniting complete antitumor immune responses providing unparalleled tumor clearance efficacy.
Founding team
Kevin Neil, PhD
Co-Founder & CSO
Sébastien Rodrigue, PhD
Co-Founder & CTO
Prof. Université de Sherbrooke
Medical Advisors
CEO of Ankyra Therapeutics
Clinical AssociateClinical Associate
Massachusetts General Hospital
Head of the Inpatient Unit in the Drug Development Department at the Gustave Roussy Cancer Campus.
Director of the Department of Oncology at the Montréal Jewish General Hospital and director of McGill University’s Centre for Translational Research in Cancer.
Business advisors
General Partner & CMO
TVM Capital Life Science VC
Director Equity Analyst Healthcare at UBP, Geneva
Scientific advisors
Jamie Scott, MD, PhD
Prof. Emerita
Simon Fraser University
CSO Ingenew Pharma
Let's get in touch.
Are you interested in collaborating with us? Feel free to contact us. We are looking forward to hearing from you!
Join us to create disruptive drugs!
We are constantly looking for talented individuals who are eager to hack biology and develop next-generation drugs.
If you want to join the team at TATUM, please send your CV and motivation letter at:
